IRA Provision: The Medicare Prescription Drug Inflation Rebate Program
The Centers for Medicare & Medicaid Services (CMS) issued a fact sheet and a list of 27 Part B "rebatable drugs":
| Abelcet | Cytogam | Leukinen | Sylvant |
| Akynzeo | Elzonris | Minocin | Tecartus |
| Atgam | Fetroja | Mircera | Winrho SDF |
| Aveed | Flebogamma DIF |
Nipent | Xiaflex |
| Bicillin C-R |
Folotyn | Padcev | Xipere |
| Bicillin L-A |
Fragmin | Rybrevant | Yescarta |
| Carnitor | Humira | Signifor LAR |
Key Considerations
- The inflation-adjusted coinsurance percentage limitation—calculated in accordance with the Inflation Reduction Act—will apply to the 27 rebatable drugs from April 1 through June 30, 2023.
- CMS will post an updated list of rebatable drugs and corresponding coinsurance adjustments each quarter as part of the Medicare Part B Quarterly Sales Pricing (ASP) file.
Next Steps for Stakeholders
- Many Medicare and Medicare Advantage beneficiaries should see reduced coinsurance or refunds for these rebatable drugs purchased after April 1, 2023.
- CMS’s determination of whether a drug is a Part B rebatable drug is considered final.
- Manufacturer suggestions of calculation errors may be submitted within 10 days after receipt of a Preliminary Rebate Report.
Related Documents
Fact Sheet: Part B Rebatable Drug Coinsurance Reduction
Reduced Coinsurance for Certain Part B Rebatable Drugs (April 1 - June 30, 2023)
Date of Issuance: March 15, 2023
More Like This
Game-Changing IRA: Revolutionizing Prescription Drug Pricing and Medicare Benefits
Inflation Reduction Act’s Drug Price Negotiation Provisions – What’s Next?
People
Associate
Board of Directors / Member of the Firm
